Charles Schwab Investment Management »

Sab Biotherapeutics shares owned by Charles Schwab Investment Management

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Charles Schwab Investment Management from 13F filings

Historical chart of Charles Schwab Investment Management investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Charles Schwab Investment Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Charles Schwab Investment Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $412k 106k 3.90

More positions owned by Charles Schwab Investment Management

NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Schwab Strategic Tr Fundamental Us L (FNDX)
Alphabet Cap Stk Cl C (GOOG)
Meta Platforms Cl A (META)
UnitedHealth (UNH)
Tesla Motors (TSLA)
Micron Technology (MU)
Schwab Strategic Tr Fundamental Intl (FNDF)
Eli Lilly & Co. (LLY)
Home Depot (HD)

View all positions for Charles Schwab Investment Management

Top funds holding Sab Biotherapeutics

Caligan Partners
Vivo Capital
Perceptive Advisors
Adage Capital Partners GP
RA Capital Management
Balyasny Asset Management
BlackRock
Vanguard Capital Management
Commodore Capital
Millennium Management
Spruce Street Capital
Sessa Capital IM
Affinity Asset Advisors
Boothbay Fund Management
Geode Capital Management

View all funds holding Sab Biotherapeutics